Sign inCreate account

Report workspace tools

NCT00849524TERMINATEDanonymous

A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Sponsor

Source record

Januario Castro, M.D.

Phase

Source record

Phase II

Modality

AI-normalized

protein therapy

Target

AI-normalized

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Indication / condition

AI-normalized

Chronic Lymphocytic Leukemia

Intervention

Source record

ISF35

Source & freshness

Source record

NCT ID

NCT00849524

Original source

ClinicalTrials.gov

Source last updated

Dec 30, 2015

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00849524

Title

A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Sponsor

Januario Castro, M.D.

Status

TERMINATED

Phase

Phase II

Condition raw

Chronic Lymphocytic Leukemia

Condition normalized

Chronic Lymphocytic Leukemia

Modality raw

Chronic Lymphocytic Leukemia

Modality normalized

protein therapy

Target raw

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Target normalized

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Interventions

ISF35

Public preview

Source record

The trial aimed to evaluate the safety and efficacy of Ad-ISF35, a cancer vaccine, administered via intranodal injection in patients with CLL/SLL. The study was conducted at the University of California, San Diego, with a total enrollment of 6 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00849524

Status

TERMINATED

Phase

Phase II

Sponsor

Januario Castro, M.D.

Executive brief

Investment-Ready Snapshot

The trial aimed to evaluate the safety and efficacy of Ad-ISF35, a cancer vaccine, administered via intranodal injection in patients with CLL/SLL. The study was conducted at the University of California, San Diego, with a total enrollment of 6 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 30, 2015
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00849524

Indication

Chronic Lymphocytic Leukemia

Modality

protein therapy

Target

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Intervention

ISF35

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.